N-[[4-[8-amino-1-(1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexyl]methyl]-1H-indole-3-carboxamide;1-(4-chloro-1H-indol-2-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-(1-propylsulfonylpiperidin-4-yl)imidazo[1,5-a]pyrazin-8-amine
C94H92ClN23O4S — CID 159037630
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[[4-[8-amino-1-(1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexyl]methyl]-1H-indole-3-carboxamide;1-(4-chloro-1H-indol-2-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-(1-propylsulfonylpiperidin-4-yl)imidazo[1,5-a]pyrazin-8-amine
N-[[4-[8-amino-1-(1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexyl]methyl]-1H-indole-3-carboxamide;1-(4-chloro-1H-indol-2-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-(1-propylsulfonylpiperidin-4-yl)imidazo[1,5-a]pyrazin-8-amine (PubChem CID 159037630) has the molecular formula C94H92ClN23O4S and a molecular weight of 1675.45 g/mol. Its IUPAC name is N-[[4-[8-amino-1-(1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexyl]methyl]-1H-indole-3-carboxamide;1-(4-chloro-1H-indol-2-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-(1-propylsulfonylpiperidin-4-yl)imidazo[1,5-a]pyrazin-8-amine.
Molecular Properties
| Compound Name | N-[[4-[8-amino-1-(1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexyl]methyl]-1H-indole-3-carboxamide;1-(4-chloro-1H-indol-2-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-(1-propylsulfonylpiperidin-4-yl)imidazo[1,5-a]pyrazin-8-amine |
|---|---|
| PubChem CID | 159037630 |
| Molecular Formula | C94H92ClN23O4S |
| Molecular Weight | 1675.45 g/mol |
| Exact Mass | 1673.71 |
| IUPAC Name | N-[[4-[8-amino-1-(1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]cyclohexyl]methyl]-1H-indole-3-carboxamide;1-(4-chloro-1H-indol-2-yl)-3-cyclobutylimidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-[1-(4-methoxyphenyl)cyclopropyl]imidazo[1,5-a]pyrazin-8-amine;1-(1H-indol-2-yl)-3-(1-propylsulfonylpiperidin-4-yl)imidazo[1,5-a]pyrazin-8-amine |
| SMILES | CCCS(=O)(=O)N1CCC(c2nc(-c3cc4ccccc4[nH]3)c3c(N)nccn23)CC1.COc1ccc(C2(c3nc(-c4cc5ccccc5[nH]4)c4c(N)nccn34)CC2)cc1.Nc1nccn2c(C3CCC(CNC(=O)c4c[nH]c5ccccc45)CC3)nc(-c3cc4ccccc4[nH]3)c12.Nc1nccn2c(C3CCC3)nc(-c3cc4c(Cl)cccc4[nH]3)c12 |
| InChI | InChI=1S/C30H29N7O.C24H21N5O.C22H26N6O2S.C18H16ClN5/c31-28-27-26(25-15-20-5-1-3-7-23(20)35-25)36-29(37(27)14-13-32-28)19-11-9-18(10-12-19)16-34-30(38)22-17-33-24-8-4-2-6-21(22)24;1-30-17-8-6-16(7-9-17)24(10-11-24)23-28-20(21-22(25)26-12-13-29(21)23)19-14-15-4-2-3-5-18(15)27-19;1-2-13-31(29,30)27-10-7-15(8-11-27)22-26-19(20-21(23)24-9-12-28(20)22)18-14-16-5-3-4-6-17(16)25-18;19-12-5-2-6-13-11(12)9-14(22-13)15-16-17(20)21-7-8-24(16)18(23-15)10-3-1-4-10/h1-8,13-15,17-19,33,35H,9-12,16H2,(H2,31,32)(H,34,38);2-9,12-14,27H,10-11H2,1H3,(H2,25,26);3-6,9,12,14-15,25H,2,7-8,10-11,13H2,1H3,(H2,23,24);2,5-10,22H,1,3-4H2,(H2,20,21) |
| InChIKey | JVQPRPMYUHNZJX-UHFFFAOYSA-N |
| XLogP | 17.95 |
| TPSA | 379.50 Ų |
| H-Bond Donors | 10 |
| H-Bond Acceptors | 20 |
| Rotatable Bonds | 16 |
| Heavy Atoms | 123 |
| Complexity | — |
Lipinski Rule of Five
4 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1675.45 |
| LogP ≤ 5 | 17.95 |
| H-Bond Donors ≤ 5 | 10 |
| H-Bond Acceptors ≤ 10 | 20 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 159037630 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.